A new cardiovascular-outcomes trial has found that Invokana (generic: canagliflozin), a type 2 diabetes drug made by Janssen Pharmaceuticals, has been linked to a doubled risk for amputation of the toes or feet.
Free Confidential Lawsuit Evaluation: If you or a loved one had an amputation after taking Invokana, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.
What’s the Problem?
July 13, 2017 – The Canagliflozin Cardiovascular Assessment Study (CANVAS) and the CANVAS renal-end-points trial (CANVAS-R) found that Invokana reduces cardiovascular events by 14% and renal decline by 40%, but doubles the risk for lower limb amputation.
The combined results from the studies were presented at the American Diabetes Association 2017 Scientific Sessions and published in the New England Journal of Medicine (NEJM).
The CANVAS data indicated what was described as a significant doubling in amputation risks, specifically of the toe or metatarsal. The risk of amputation is greatest among patients with previous amputations, peripheral vascular disease, and neuropathy.
The amputation risk had been previously identified, leading to a boxed warning for canagliflozin in May 2016, as well as warnings on all SGLT2 inhibitors by the European Medicines Agency (EMA) in February.
Do I Have an Invokana Class Action Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Invokana lawsuits. We are handling individual litigation nationwide and currently accepting new amputation cases in all 50 states.
Free Case Evaluation: Again, if you were forced to have an amputation after being treated with Invokana, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.